"Pemetrexed" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A guanine-derived ANTINEOPLASTIC AGENT that functions as a NUCLEIC ACID SYNTHESIS INHIBITOR through its binding to, and inhibition of, THYMIDYLATE SYNTHASE.
| Descriptor ID |
D000068437
|
| MeSH Number(s) |
D03.633.100.759.758.399.454.650 D12.125.067.625.525 D12.125.119.409.525
|
| Concept/Terms |
Pemetrexed- Pemetrexed
- MTA
- N-(4-(2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid
LY 231514- LY 231514
- 231514, LY
- LY-231,514
- LY231514
- LY 231,514
- 231,514, LY
- LY-231514
|
Below are MeSH descriptors whose meaning is more general than "Pemetrexed".
Below are MeSH descriptors whose meaning is more specific than "Pemetrexed".
This graph shows the total number of publications written about "Pemetrexed" by people in this website by year, and whether "Pemetrexed" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pemetrexed" by people in Profiles.
-
Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer. Am J Clin Oncol. 2015 Dec; 38(6):605-9.
-
Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer. J Clin Oncol. 2015 Jan 10; 33(2):189-94.
-
Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. Ann Oncol. 2011 Nov; 22(11):2501-2507.